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Gene therapy strategies have been intensively studied for over 20 years. However, 
there are yet no gene therapy protocols in conventional use. In this project, a gene 
delivery protocol was optimized for the transient delivery of mRNA molecules into 
two human cancer cell lines with the purpose of disclosing novel S100A4 gene 
interactions as a result of S100A4 overexpression. 
The Enhanced Green Fluorescent Protein (EGFP) and the metastasis-promoting 
S100A4 gene were used in this study. To deliver mRNA molecules we investigated 
the potential of two different delivery vehicles, the bio-compatible transfection carrier 
β-cyclodextrin and the well characterized polyethylenimine (PEI) carrier.  In addition, 
we evaluated the possibility for targeted mRNA delivery by the use of photochemical 
internalization (PCI) technology, a site-specific delivery strategy. Our results showed 
that PEI was an effective carrier for delivery of mRNA either with or without PCI, 
which was in contrast to β-cyclodextrin.  
To evaluate potential novel S100A4 gene interactions we preformed microarray 
profiling of two S100A4 mRNA overexpressing cell lines (OHS and LOX). Some of 
the most affected genes were chosen for reverse transcriptase quantitative PCR 
verification. The transporter lipocalin 12 and the collagen precursor Col1a2 were 
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Cancer is a generic term describing a large group of conditions caused by 
uncontrolled cell growth within the body, and is also referred to as malignant tumors 
or neoplasms. Cancer takes its name from the Greek word for crab, karkinos, due to 
the crab-like projections seen in some malignant tumors. [1]   
 
1.1.1 Relevance of studying cancer 
Cancer beats ischaemic heart disease as the number one cause of death in the 
developed world according to World Health Organization reports, accounting for one 
in eight deaths worldwide. [2, 3] Since American President Richard Nixon essentially 
gave the cancer research community carte blanche in the 1971 Cancer Act, [4] an 
enormous effort has been put into cancer research and treatment. Still, cancer 
incidence continues to rise internationally, even when correcting for population 
growth, and especially in developing countries. This is partly due to increased life 
expectancies and improved methods of diagnosis. [2] The need for a continued effort 
to work out the molecular causes of the condition is evident. 
Studying cancer can also give a greater understanding of healthy biology. By 
detecting the genetic and epigenetic changes in a cancer and observing their effects 
on the functions of the cell, insights about the normal function of the genes can be 
derived. 
 
1.1.2 Cancer as a microevolutionary process 
Cells in a multicellular organism are tightly controlled to act as constituents of a 
whole, and will normally never divide unless stimulated by their environment to do 
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so. Cancerous cells behave more like single celled organisms; dividing as much as the 
available resources allow. This loss of top-down control arises from random 
mutations in the genomes of individual cells. Active, metabolizing human cells are 
continuously subject to DNA damage, estimated to ~800 lesions per cell per hour. [5] 
The vast majority of the damages are rapidly reverted by efficient DNA repair 
systems, but those that are not repaired correctly stay in the genome as mutations 
(alterations of the DNA sequence). Mutations accumulate over time and are preserved 
in subsequent cell divisions. This is the main reason why cancers most often occur in 
old age. [6] Cancer-promoting mutations can be divided into two groups: those that 
cause loss of function or down-regulation of tumor suppressor genes, and those that 
enhance expression or function of proto-oncogenes. Additionally, mutations that 
impair the DNA repair machinery or epigenetic mark-up of DNA facilitate cancer 
progression by promoting further genetic damage and dysregulation. 
Due to redundancy and backup mechanisms, no single mutation can cause cancer 
alone, but multiple mutations in vital genes put the cell at risk of evading the normal 
restrictions on proliferation. [6, 7] 
A set of phenotypical properties necessary for cancer development termed the 
hallmarks of cancer were posted by Hanahan and Weinberg in 2000; self-sufficiency 
in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis 
(programmed cell death), limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis. Mutations promoting one (or multiple) of these 
hallmarks make the cell more likely to persist, survive, and divide uncontrolled. [8] 
The hallmarks are illustrated in figure 1.1. 
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Figure 1.1: The cancer hallmarks. phdcomics.com, used with permission. 
The complexity of cancer genetics is immense; no two cancer cases have the same 
genetic profile. Still, some mutations are frequently found in cancers. What these 
mutations have in common is giving the affected cell a selective advantage in the 
environment that is our body.  
 
1.1.3 Changes in gene expression in cancer 
The human genome contains more than 20 000 genes, of which roughly half are 
expressed in all cells at all times (these are called household genes), and the rest are 
specific to certain tissues or cell types, or expressed only in response to certain 
stimuli. Any one cell expresses less than a thousand specific genes, which give them 
their defining traits. [9]  The rest of the genome is locked away by epigenetic 
packing, mainly DNA methylation. [10] 
When a gene is expressed, it is transcribed to mRNA in the nucleus, complexed with 
chaperone proteins and transported out into the cytoplasm where it is translated to 
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protein by ribosomes. All steps in this process are subject to regulation (see [6] p 
415). 
As all cells contain the entire genome, any cell may by accident gain access to genetic 
information that is normally not accessible to them. When this happens in genes that 
take part in the tight regulation of cell fate, control mechanisms may be 
compromised. Such changes may occur through a decrease in DNA methylation, 
mutations in the regulatory elements that keep the gene turned off, or chromosomal 
rearrangements that put the gene in a close proximity to a strong promoter sequence. 
Conversely, tumor suppressor genes are often observed to be down-regulated in 
cancer. [10] 
 
1.2 Gene therapy 
Genetic diseases are caused by mutated or otherwise malfunctioning genes. Gene 
therapy seeks to correct genetic diseases by inserting normal copies of the gene into 
cells, or remove the expression of the erroneous gene. The experimental insertion of 
genetic material (DNA or RNA) into cultured cells is called transfection (trans - from 
the outside). Vectors that can be used for transfection include engineered viruses, 
ribozymes, locked RNA (LNA), and peptide nucleic acids (PNA). Gene therapy has 
been proposed as treatment for a wide range of conditions including cystic fibrosis, 
[11] Parkinson’s disease, [12] Huntington’s disease, [13] severe combined 
immunodeficiency (SCID; [14]) and cancer. [15], [16] 
After 20 years and over 1500 clinical trials, gene therapy is yet to be implemented in 
the clinic, with the notable exception of immunotherapy using transfected immune 
cells. [17] The main problems have been the controlled and safe integration of DNA 
into the genome, adverse immune responses against the transfection agent or the 
transgene, in addition to cytotoxicity (cell death caused by the transfection itself or 
the overexpressed gene). [18] 
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1.2.1 Gene therapy in cancer 
As cancer is a genetic disease, the notion of correcting it with gene therapy is 
compelling. However, despite tremendous efforts over many years, these approaches 
are still experimental. As mentioned in section 1.1, cancer is caused by a range of 
defects acting in concert, and differently in every single patient. By reverting some, 
but not all of the changes in the cancerous cell, the cancer could become more likely 
to evade apoptosis, thereby becoming more severe. Also, unlike hereditary genetic 
diseases in which the genetic defect is present in all cells, a cancer is surrounded by 
normal tissue that preferably should be untreated to avoid off-target effects. A site-
directed delivery method for gene therapy is therefore preferable to target the 
cancerous cells. 
 
1.2.2 Transfection agents 
Two cationic transfection agents were used in the study, alone and in combination 
with light-directed endosomal rupture (PCI). 
Polyethylenimine 
The organic, polycationic polymer polyethylenimine (PEI; H(NHCH2CH2)nNH2)  is a 
cost-efficient excipient (carrier) for in vitro transfection. [19, 20] It may, however,  be 
less suited for in vivo applications due to reported cytotoxic effects of compromising 
the integrity of the plasma membrane[21] and mitochondria membranes. [22] 25 kDa 
branched PEI was selected, on the basis of being well characterized and known to 
produce high transfection rates when combined with either siRNA or mRNA 
molecules. [23, 24] 
When using this carrier, the charge of the transfection complex is essential for uptake 
into cells. The theoretical charge is calculated from the ratio between Nitrogen and 
Phosphate (N/P) in the complex, as these are the charge-bearing elements present in 
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the compounds. At neutral pH, all phosphate groups on mRNA bear a negative 
charge, while around one in three amine groups on PEI bear a positive charge. [25] 
To find the charge of the complex, the N/P ratio is therefore divided by 3. It is 
assumed that the ratio of RNA molecules to PEI molecules within each complex is 
the same as the overall ratio in the mix. 
a)                                 b)        
c)  
Figure 1.2. (a) Monomer structure of PEI. (b) Branched PEI. [26] (c) Graphical 
summary of polyplex formation and internalization of mRNA molecules complexed with 
PEI. The polyplexes have a net positive charge, and adhere to the negatively charged plasma 
membrane by electrostatic interactions. Note that polyplexes consist of multiple RNA and 
PEI molecules. Figure adapted from Agner, [27]. 
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The carrier shields the mRNA, protecting it from degradation by RNAses. The 
mRNA/carrier complexes have a net positive charge due to the higher concentration 
of PEI than mRNA in the mix, and therefore associate to the cell membranes, which 
have a net negative charge due to glycosylations and phosphorylations on surface 
proteins. [28] When the membrane with mRNA/PEI polyplexes attached is 
endocytosed, the polyplexes will be incorporated in the endosome as illustrated in 
figure 1.2c. 
At high concentrations (1.5*10
-2
 µg/µl), PEI itself causes rupture of endosomal 
membranes, presumably due to osmotic pressure caused by increased protonation 
level of PEI in the low pH conditions in the endosomes (the proton sponge effect), 
with subsequent influx of Cl
-
 and H2O. [25] At low concentrations (below 10
-2
 µg/µl), 
the proton sponge effect is not strong enough to disrupt the endosomal membrane and 
PEI is thereby entrapped in the lysosomal pathway unless released by other agents. 
β-cyclodextrin 
A bio-compatible carrier was also assessed for use in mRNA transfection. 
Cyclodextrins (CDs) are a group of cyclic oligosaccharides forming a toroidal shape 
with a somewhat hydrophobic inside and a more hydrophilic outside caused by 
outwards oriented hydroxyl groups. [29] CDs are capable of forming inclusion 
complexes with hydrophobic particles of the right diameter. [30] CDs with six, seven 
or eight glucose units (α-, β-, and γ-CDs, respectively) occur naturally in the human 
body where they act in the transport of specific hydrophobic molecules. [31] CDs are 
widely used in biomedicine as solubilizers, stabilizers or excipients alone or 
covalently bound to other functional groups. [32] The CDs are generally considered 
as bio-tolerable, although some formulations, including β-CD, are nephrotoxic.  [33] 
β-cyclodextrin (1135 Da) consists of seven glucose molecules, giving a cavity 
diameter of 6.0-6.5 Å. [32] β-CD-based carriers have been characterized for use with 
oligonucleotides (siRNA), [34] but are not well described for  mRNA transfection. A 
β-CD polymer linked with 6 methylene units (β-6CDP; figure 1.3), with Mw 
averaging 8.8 kDa corresponding to 6 units of β-6CD, and charge averaging +12 per 
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molecule, was used in this study. In contrast to monomeric β-CD, this polymer has 
good solubility. It is able to form complexes with nucleic acids based on electrostatic 
interactions. The resulting complexes are positively charged, and may therefore 
adhere to the cell surface by the same principle as PEI-based complexes. [35] 
  
Figure 1.3: Structure of β-cyclodextrin polymer with 6 methylene units (β-6CDP). Figure 
from Bøe, [34]. 
 
Light directed gene delivery: PCI 
The PhotoChemical Internalization (PCI) method was developed at the Radium 
Hospital for enhanced delivery of genetic material or other compounds into the 
cytosol of cells in a site-specific manner. [36] The method enables endocytosed 
material to escape the endocytic pathway by light-induced rupture of endosomal and 
lysosomal membranes.  
An amphiphilic photosensitizing compound that is designed to be activated by light 
of a certain wavelength is added to the cells along with the drug to be delivered. The 
photosensitizing compound associates to lipids in the cell membranes. As the drug is 
endocytosed, photosensitizer molecules will be associated to the membranes of 
endocytosed vesicles. 
When illuminated at the appropriate wavelength, the compound absorbs the light 
energy in its conjugated chemical bonds, producing highly reactive oxygen species 
(ROS), mainly singlet oxygen. ROS may induce damage to nearby molecules such as 
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fatty acids and thereby create holes in endosomal and lysosomal membranes leading 
to release of entrapped material into the cytosol. ROS have a very short reaction 
range due to antioxidative compounds in the cell. [37] 
In clinical trials, PCI treatment has shown to mediate efficient drug delivery to cancer 
patients. [38] By illuminating the tumor only, the construct was taken up specifically 
by cells in the tumor, and the impact on the rest of the body was reduced. [39] In the 
current study, PCI treatment was assessed for use with the aforementioned system as 
a move toward in vivo applications. 
 
1.3 Endocytosis 
Endocytosis is a collective term for a range of mechanisms through which cells take 
up extracellular material. The endocytic pathways (summarized in figure 1.4) can be 
roughly divided into two groups;  
 pinocytosis, which can be clathrin-dependent (~100 nm),  caveolar (~50 nm), clathrin-
independent or macropinocytosis (0.5-5 µm) 
 phagocytosis, which happens primarily in cells of the immune system [40] 
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Figure 1.4: Summary of the endocytic pathways. Pinocytosis mechanisms pictured: 1. 
clathrin coated vesicles, 2. caveolae, 3. non-coated vesicles and 4. macropinocytosis. Figure 
from Marsh, [40]. 
Many of the steps involved remain obscure, and new mechanisms for endocytosis are 
still being discovered [41]. All pathways involve entrapping the material to be 
endocytosed in a pocket in the plasma membrane formed by cytoskeleton remodeling. 
The pocket is pinched off as a membrane-enclosed compartment in the cytosol, and 
typically fuse with an early endosome (pH 6). The pathway continues through 
endosomal compartments with a progressively acidic environment due to vascular H
+
 
ATPase activity, until arriving in the lysosome (pH 4.5-5). Acid hydrolases and other 
degrading enzymes in the endosomes and lysosomes are activated by low pH. [42, 
43] Endocytic vesicles are very dynamic, often undergoing fusion and fission events. 
Throughout the pathway, the cargo is trapped within membrane enclosed 
compartments and will normally not be in contact with the cytosol before it is 
digested in the lysosome.  
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Phagocytosis is the main internalization mechanism for particles exceeding 200 nm in 
size, according to Marsh. [40] Most phagocytosis occurs by the professional 
phagocytic cells of the immune system, but also other cell types, including fibroblasts 
and epithelial cells, are capable of phagocytosis. [44] Phagocytosis is initiated by 
cytoskeleton induced protrusions of the cell membrane around the particle, engulfing 
the particle in a large vesicle called a phagosome. Phagosome maturation parallels 
endosomal maturation, as illustrated in figure 1.5, also in terms of pH change, due to 
considerable exchange of material by vesicular transport or organelle fusion.  
 
Figure 1.5: Phagosomal and endosomal maturation. From Rosales, [44]. 
Different cell types may have varying endocytic capacities by the different 
mechanisms. Inhibition studies of the endocytosis of particles of similar size to the 
particles used in the current study, suggest that multiple endocytic pathways 




S100A4, also known as Mts1, p9Ka or metastatin, is a human gene normally 
expressed in certain cell types including some types of immune and endothelial cells. 
The name refers to the solubility of the first identified S100 proteins in 100% 
saturated ammonium sulphate. [46] The gene codes for a small (101 amino acids per 
chain), usually di- or oligomeric protein with two Ca
2+
-binding EF hands on each 
chain. [47] Upon Ca
2+
 binding the conformation of the protein is altered, exposing a 
hydrophobic pocket which can interact with target proteins. It thereby acts as a Ca
2+
-
sensor. [48] In the dimeric form, both S100 subunits form hydrophobic pockets and 
can thus bind two target proteins at the same time, bringing them together. 
The reported cellular locations of S100A4 span from the extracellular space and 
cytosol to the nucleus. While the protein has no enzymatic activity on its own, it 
binds other proteins and influences their activity by altering their conformation. In the 
nucleus, it is presumed to modulate transcription of target genes. When secreted, it is 
reported to initiate auto- or paracrine signaling pathways. [49]  
Ectopic expression of S100A4 in cancer affects several of the cancer hallmarks: 
angiogenesis, survival and metastasis, [49, 50] and is correlated with adverse 
prognosis for the patient (higher-grade tumors and shorter life expectancy). [51] 
S100A4 has been proposed as a prognostic marker in several cancers including 
colorectal cancer. [52] The gene tends to show up in expression profiles of cancerous 
cells from many cell type origins. This may be caused by the general 
hypomethylation often found in cancer. [53] Because of this, the gene has been 
subjected to a lot of interest from cancer researchers for years; however, its precise 
roles in cancer propagation are not yet fully elucidated at a molecular level.  
Identifying target genes for the activator function of S100A4 is one approach to 
investigating the role of the protein in cancer propagation.   
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1.5 Aims of the study 
The aim of the current study was to optimize a method for mRNA delivery into 
human cancer cell lines. Furthermore, to demonstrate that the strategy can be 
combined with microarray profiling to disclose interaction networks and reveal gene 
functions.   
The S100A4 gene was chosen due to its ability to affect several of the hallmarks of 
cancer: angiogenesis, survival and metastasis. S100A4 has been characterized 
extensively by others, often by removing the expression of the gene using e.g. siRNA 
molecules. [52, 54, 55] In order to validate these findings by another approach and 
possibly identifying novel target genes, a method for transfecting cells with mRNA 
was optimized for two human cancer cell lines (OHS and LOX). Two different 
carriers were tested for mRNA transfection. In addition, we explored the possibility 
for targeted mRNA delivery by combining with PCI, a promising strategy for site-
specific transfection in vivo.  
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2. Materials and Methods 
2.1 Cell work 
The aims of the study involved optimizing a method for mRNA delivery into cells, 
and demonstrating the possibility to disclose novel S100A4 gene interactions after 
expression profiling. For these applications human cancer lines are preferable to work 
with, as cultured cells are easy to grow and transfect in a controllable manner.  
 
2.1.1 Cell culture 
Two different human cancer cell lines with well characterizes S100A4 status were 
used in the study; the osteosarcoma cell line OHS which has high S100A4 
expression, and the melanoma cell line LOX, which is negative for S100A4 
expression. Both cell lines were established from patients at the The Norwegian 
Radium Hospital, and have been cultivated for several years. [56, 57]  
Cells were grown in 75 cm
2
 flasks (Nunc, Roskilde, Denmark) containing RPMI 
medium (BioWhittaker, Verviers, Belgium) with 2mM L-glutamine (GlutaMAX; 
GibcoBRL, Paisley, UK) and 10% fetal calf serum (FCS;  BioWhittaker, Verviers, 
Belgium)  at 37
o
C in humidified atmosphere containing 5% CO2. Cell cultures were 
passaged two to three times per week by adding 1 ml trypsin (BioWhittaker) when 
reaching approximately 90% confluency. Trypsin is a serine protease that breaks 
down the extracellular proteins that adhere cells to the surface of the vessel. 1/8 to 
1/10 of the cell culture was passed on in each passage. The remaining culture was 
used for seeding or discarded. 
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2.1.2 Plating of cells 
In order to seed the correct number of cells, suspended cells were counted using a 
manual click counter and a Bürke chamber (Kova Glasstic; Hycor, CA, USA); a 
microscope slide with a chamber accommodating a fixed volume of cell culture and a 
grid for counting.  
For the OHS cell line, approximately 80 000 cells were plated per well in 6-well 
plates or approx. 45 000 in 12-well plates. The LOX cell line divides slightly faster, 
and approx. 75 000 and 41 000 cells were plated, respectively. Cells were incubated 
at 37
o
C for approx. 48 hrs until cells were 50-60% confluent.  
2.1.3 Freezing and thawing cells 
In a cell culture that is allowed to run for an extended period of time, random 
mutations will accumulate in the genomes of the cells, possibly altering the properties 
of the cell culture over time. In order to minimize such variation, cell cultures were 




C is defined as cryogenic temperature. [58] At cryogenic temperature, 
cells are virtually indefinitely stable. [59] 
Freezing procedure:  
When needed, cells were frozen by a slow-freeze method using dimethyl sulfoxide 
(DMSO; Sigma-Aldrich) as a cryoprotectant, preventing formation of damaging 
crystals in the freeze-culture. 
DMSO is toxic to metabolically active cells and should therefore be added 
immediately before freezing. Rubber gloves should be used as the compound 
dissolves nitrile.  
Prior to freezing, medium was discarded from a 90-95% confluent, actively growing 
cell culture. Cells were detached from the surface by the use of 1 ml trypsin. After 
detachment, cells were diluted in 10 ml medium, and 9 ml of the suspended cell 
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culture was pelleted and re-diluted in 9 ml freeze medium (Appendix E).  The rest of 
the cell culture (1 ml) was passaged, except for 100 µl, which was used for testing 
against Mycoplasma infection. The freeze medium was divided into 9 labelled 
microvials and slow-frozen for 24 hrs at -80
o
C in a Nalgene Cryo freezing container 
(Thermo Sci) filled with isopropanol. The freezing container was then transferred to a 
-180
o
C freezer. After 24 hrs at -180
o
C the microvials were transferred from the 
freezing container to a separate “quarantine” box. The microvials were kept in the 
quarantine box until the Mycoplasma test was confirmed negative.  
Thawing procedure: 




C for rapid thawing. The vial 
was desinfected with 70% EtOH before opening. Once liquid, the cell culture was 
immediately transferred to a 75 cm
2
 cell culture flask and an ample amount of growth 
medium was added to dilute the freeze medium. When the cells adhered to the bottom 
surface (after 24-30 hrs), the medium was replaced with fresh medium to remove 
residual DMSO.  
The morphology and gene expression profile of newly thawed cells may differ from 
normal. The culture was therefore passaged at least two times before use in 
experiments.  
 
2.1.4 Mycoplasma testing 
All cell lines were routinely tested for Mycoplasma infection using the PCR 
(Polymerase Chain Reaction)-based VenorGeM® Mycoplasma Detection kit 
(Minerva Biolabs, Berlin, Germany) by in house laboratory staff every 6 weeks. At 
90-95% cell confluence, 100 µl of medium was transferred from culture flasks to 
sterile microtubes and stored at -20
o
C until analyzed. PCR was performed using 
primers specific for the conserved 16S rRNA coding region in the Mycoplasma 





Transfection is a method for transferring macromolecules, usually genetic material, 
into cells. In this study, messenger RNA (mRNA) for our gene of interest was 
transfected into two different human cancer cell lines and used by the cells as a 
transient template for producing protein. 
Multiple transfection protocols are available for mRNA transfection, including 
microinjection, electroporation, and complexation with lipid or cationic excipients. 
The transfection carrier serves two purposes:  
 Transporting the mRNA through the cell membrane. 
 Protecting the easily degradable mRNA molecules until arrival in the cytosol, where the 
mRNA must become accessible for the translation machinery.  
All transfection implies transport through the cell membrane, compromising the 
barrier that ensures homeostasis within the cell. Extensive optimizations were 
performed in order to minimize cell toxicity while obtaining high transfection 
efficiency. 
Transfection procedure 
Both cell lines were transfected transiently with S100A4 mRNA at 50-60% 
confluency (~0.5 – 1 x 106 cells) two to three days after seeding, using 25 kDa 
branched PEI (Sigma-Aldrich) or 8.8 kDa β-6CDP (Gift from Mark E Davis, 
California Inst. of Technology) with or without PCI technology (described below).   
Transfection agent and mRNA were added to 200 µl serum-free medium and allowed 
to form complexes for 30 minutes. After complex formation, the complex solution 
(200 µl per transfection) was added to wells containing cells and 800 µl serum-
containing medium.  
For PEI-based transfections, a broad concentration assay was used initially, before 
converging on the concentrations that showed the highest transfection efficacy with 
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lowest cytotoxicity. For β-6CDP-based transfections, three concentrations that had 
shown good efficiencies in earlier siRNA based studies [34] were selected for use 
with mRNA. Typical amounts of transfection reagent and mRNA are listed in table 
2.1.  
Table 2.1: a) Typical ratios of mRNA and PEI used in non-PCI (top) and PCI-assisted 
(bottom) transfections. b) Amounts of β-6CDP and mRNA used in β-6CDP-based 
transfections. All amounts are given as µg per tranfection. All complexation was done in 200 
µl serum-free medium. 
PCI PEI (µg) RNA (µg) N/P 
- 3.0 1.0 22 
- 3.0 2.0 11 
- 3.0 3.0 7.3 
+ 0.4 1.0 3 
+ 0.7 1.0 5 
+ 1.1 1.0 8 
+ 1.4 1.0 10 
a)  
PCI β-6CDP (µg) RNA (µg) 
+ 12.5 1.0 
+ 25 1.0 
+ 50 1.0 
b)   
 
2.2.1 Transfection using PCI 
The PhotoChemical Internalization (PCI) method (introduced in section 1.2.1) was 
used in some of the experiments to investigate the possibility for enhanced 
transfection efficiency in a site-specific manner. The photosensitizer used in the light-
enhanced experiments was meso-tetraphenylporphine with 2 sulfonate groups on 
adjacent phenyl rings (TPPS2a; Frontier Sci, Logan, USA. See figure 2.1).  
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Figure 2.1: TPPS structure. In TPPS2a, 2 neighboring R groups are sulfonate. The molecule 
is extensively conjugated, absorbing light at 420 nm. 
This amphiphilic photosensitizer localizes to the cell membranes, and will be 
internalized in endocytic vesicles. When treated with blue light, an oxidative reaction 
is initiated which leads to membrane damage and subsequent release of endocytosed 
material including mRNA/carrier complexes into the cytosol where mRNA is 
translated.  
Procedure: 
mRNA/PEI complexes were prepared as described in section 2.2.1. For PCI 
treatment, 8 µl TPPS2a was added to 12.5 ml RPMI medium containing serum and 
glutamine. 800 µl of the sensitizer-containing medium was added to each well, along 
with 200 µl of mRNA/PEI complexes, giving a final TPPS2a concentration of 0.5 
µg/ml. After an 18 hours incubation, cells were washed three times to remove excess 
photosensitizer followed by a 4 hrs re-incubation step (chase) prior to 30 seconds of 
illumination (peak wavelength 420 nm) using a LumiSource light source (7 mW/cm
2
; 
prototype, PCI Biotech, Oslo, Norway). The washing steps with the following chase 
reduces cell membrane damage as a large portion of the photosensitizer in the cell 
membrane will be either washed away or renewed during the 4 hrs incubation time. 
Expression analyses were performed after 20-24 hours. All procedures involving 
TPPS2a were conducted in dimmed light, and cells treated with TPPS2a were protected 
from light using aluminum foil. 
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2.2.2 Particle size measurement 
Particle size can be operationally defined as the diameter of a sphere that diffuses at 
the same speed as the particle being measured.  
Particle size is calculated from the Brownian motion, the “random walk” observed in 
all particles in solution. The speed of the random motion is proportional to particle 
size. [61] Information about the size and dispersity of transfection particles can give 
clues about the mechanisms that can act in their internalization. 
Procedure:  
Particle sizes of transfection polyplexes were measured using a Zetasizer Nano-ZS 
(Malvern Instruments, Worcestershire, UK) with software Zetasizer 6.01 using a pre-
defined protocol (SOP) that contains information about the solvent, the cuvette used 
in the measurements, and expected range of particle sizes.  
Polyplexes were prepared as described in section 2.2.1, and allowed to assemble for 
30 minutes. 60 µl of the complexation mix was used to measure particle sizes in a 
micro cuvette (ZEN0040; Malvern). The measured particle sizes were exported to a 
text file. 
Incubation time is an important factor influencing complex size, and each 
measurement takes a significant amount of time (3 minutes). The position of each 
sample in the measurement series is therefore expected to influence the measured 
particle size. To minimize this effect, the sample order was randomized. 
 
2.3 Flow Cytometry 
Flow cytometry is a very accurate, efficient, and reliable method for the detection of 
light scattering, as well as fluorescence in individual cells. Cells travel past the lasers 
one cell at a time in a fluid stream (figure 2.2). Scattered light is detected and 
information about size, granularity and fluorescence for the individual cells is derived 
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from the scattering pattern. Forward scatter (FSC) is detected at angles close, but not 
equal to the direction of the laser beam. Reflection at small angles gives information 
about cell size. Side scatter (SSC) is detected at angles close to 90
o
. Reflection at 
wide angles gives information about the granularity (amount of solid content) within 
the cell. [62] 
 
Figure 2.2: Flow cytometer diagram. Adapted from Strand, [63]. 
In the present study, a BD LSR II flow cytometer (BD Biosciences, NJ, USA) was 
used to quantify expression of a transfected protein, in order to assess transfection 
efficiency. As S100A4 cannot be detected by flow cytometry, the fluorescent reporter 
protein EGFP (enhanced green fluorescent protein) was used as a substitute. 
Transfection efficiencies using EGFP and S100A4 mRNA are assumed to be 
comparable in this experiment. EGFP has its absorption maximum at 489 nm and 
emission maximum at 509 nm (see figure 2.3). 
The nucleic acid intercalating agent propidium iodide (PI; Invitrogen, Carlsbad, 
USA) was used to detect dead cells. This fluorochrome enters through holes in the 
membranes of dead cells, and is generally excluded from live cells when using low 
concentration and short incubation time. When bound to DNA or RNA, it emits a red 
light with peak at 620 nm when excited at 561 nm. ([64], page 46)   
 31 
Procedure 
Cells were transfected according to section 1.2.1 with or without PCI treatment. 24 
hrs after transfection, cells were trypsinized, resuspended in 750 µl growth medium 
and transferred to flow cytometry tubes with a cell-strainer filter cap (Falcon; BD 
Biosciences). The filter cap removes cell aggregates. 1 µl PI was added to each 
sample just prior to analysis. 
EGFP and PI were excited at 488 and 561 nm, respectively. Emitted light at 510-520 
and 622-630 nm was detected (see figure 2.3). 10 000 events were recorded per 
sample. Events include not only cells but also cell fragments and other particles that 
may be present in the suspension.  
Results obtained were analyzed on FACSDiVa software version 6.1.2. PI positive 
cells, cell fragments, and doublets not removed in the filtration step (particles of large 







Figure 2.3 shows EGFP (a) and PI (b) spectra plotted with wavelength on the horizontal axis 
and relative brightness on the vertical axis. Excitation spectra are shown with dotted lines, 
emission spectra in solid color. The laser used for excitation is shown with a vertical line. 
The figure was made by using BD software [65]. 
 
 
Figure 2.4: Screen shot of FACSDiVa flow cytometer software. In this example, EGFP 
transfection efficiency is 61.9% in living single cells. EGFP positive, single, PI negative 




EGFP transfected, fluorescent cells were also viewed in a fluorescence microscope 
with a 488 nm filter (Axiovert 200M, Zeiss, Obercochen, Germany) for an overview 
of the transfection efficiency as well as cell confluency and morphology within each 
sample. Images were captured using the associated AxioCam CCD camera and 
processed using AxioVision software. 
 
 
2.5 RNA expression analyses 
Two different strategies for quantifying mRNA were employed in the study.  
qPCR is a very sensitive method for quantifying the expression of a smaller number 
of genes of interest. A typical workflow would be as follows; isolating RNA from 
harvested samples, transcribing the RNA to the more stable form DNA (denoted 
cDNA where c stands for copy), designing specific primers for the gene(s) of interest 
following detection of expression levels by qPCR. 
When quantifying the expression of a large number of genes, qPCR quickly becomes 
very laborious and time-consuming. An expression microarray experiment profiles 
the entire transcriptome in one run, measuring the level of transcription of each gene 
in the genome of the relevant species. An expression profile gives very 
comprehensive information, but at a relatively high cost. 
 
2.5.1 Isolation of RNA 
20 hours following transfection, total RNA was isolated using GenElute Mammalian 
total RNA Miniprep kit (Sigma-Aldrich) as described in the manufactures protocol 
with the following adaptions: 
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 Cells were lysed directly in the wells using freshly prepared lysis solution/2-
mercaptoethanol mixture. 
 In the final eluation, the eluation solution was transferred back on the column for a second 
eluation in order to increase yield. 
 
RNA concentration and A260/A280 ratio were measured using a Picodrop 
spectrophotometer (Thermo Fisher Sci, Waltham, USA). RNA and DNA absorb light 
at 260 nm, whereas protein (aromatic residues) absorbs light at 280 nm. An 
absorbance ratio of 260/280 nm below 1.8 implies protein contamination in the 




2.5.2 Precipitating RNA 
When necessary, RNA samples were precipitated to increase concentration using the 
following protocol: 
 Add 1x volume isopropanol and 0.1x volume sodium azide  
 Precipitate over night at -20oC 
 Centrifuge for 40 minutes at maximum speed (13 000x G or more) at 4oC.  
 Carefully remove the supernatant.  
 Wash the pellet with ~100 µl 75% EtOH 
 Centrifuge at maximum speed, 15 minutes 
 Remove supernatant, dry the pellet for a few minutes with open lid. Too long air dry will 
impair solubility. 
 Dissolve the pellet in the desired volume of the eluation buffer used in RNA isolation.  
 
2.5.3 DNAse treatment 
When necessary, traces of DNA were removed using DNAse. This was done prior to 
amplification of transcripts lacking introns. For treatment of 1 µg RNA; 1 µl DNAse 
I, 1 µl buffer and RNAse free H2O to a total volume of 20 µl (all reagents: 
Invitrogen) were added. Samples were incubated at room temperature for 15 minutes; 
DNAse was then inactivated by adding 2 µl EDTA and incubating samples for 10 
minutes at 65
o




2.5.4 cDNA synthesis (reverse transcriptase PCR) 
cDNA was prepared from 1 µg of total RNA in PCR tubes (200 µl) using qScript 
cDNA synthesis kit (Quanta, Gaithersburg, USA) containing random and oligo-dT 
primers, enabling reverse transcription of total RNA content. 
The reaction was done on a GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems, Foster City, USA) programmed using table 2.2. 
 
 Table 2.2: Temperature cycle used in cDNA synthesis. 
Temperature Time Function 
25 
o
C 5 min Stabilizing samples 
42 
o
C 30 min Annealing primers, transcription 
85 
o





cDNA was stored at 4
o
C. Assuming 100% reaction effectiveness, the cDNA 
concentration is 50 ng/µl. Prior to quantitative PCR, all samples were diluted with 
sterile H2O to 15 ng/µl.  
 
2.5.5 Quantitative PCR  
Quantitative PCR (qPCR) was used to compare the amounts of mRNAs of interest 
between samples. The iQ SYBR Green Supermix (Bio-Rad, Hercules, USA), 
containing dNTPs, iTaq DNA polymerase, dsDNA-activated fluorescent dye and 
buffer, was used for the reactions. Primers (forward and reverse strand) for the gene 
in question were used along with primers for two household genes; RPLP0 (large 
ribosomal protein) and TBP (TATA binding protein).  
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Primer design 
Custom primers were designed using the Roche Universal probe library [66] and 
PrimerBlast [67] online tools and quality controlled using the following criteria (in 
accordance with [68]): 
 Transcript length 60-90 bases 
 Primer length 18-21 bases 
 GC nucleotide content 50-65% 
 Melting temperature (Tm) preferably 58-61
oC 
 Dinucleotide repeats of more than 3 repeats and single base repetitions of more than 3 
bases were avoided 
 Primer candidates were analyzed for secondary structures (hairpins and dimerizations) 
using the IDT OligoAnalyzer [69]. 
  
All primers were purchased from MedProbe (Oslo, Norway) and diluted to 10 pm/µl 
before use. Primer sequences are listed in Appendix C. 
qPCR procedure 
Master mixes containing iQ Supermix, primers, and sterile H2O were prepared 
according to the manufacturer’s direction (see Appendix E), one master mix per pair 
of primers. 
Master mixes were distributed carefully into PCR tubes (one tube per sample), 50 µl 
per tube. 10 µl of cDNA template was added to each tube. A negative control 
containing H2O in place of cDNA was prepared for each of the master mixes. Each 
sample was distributed in two wells in a 96-well PCR plate (25 µl per well) and the 
plate was sealed with optical film (Bio-Rad). 
The qPCR reaction was run on an iCycler thermal cycler (Bio-Rad) with iCycler 
software version 3.1.7050 programmed with the following temperature cycle (listed 
in table 2.3): Initial denaturation to separate compatible cDNA strands and activate 
the engineered polymerase, followed by 42 cycles of annealing and denaturing (steps 
2 and 3). In the final cycle, the denaturing step was extended to ensure full strand 
separation, after which the samples were gradually cooled down.  
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Table 2.3: qPCR temperature cycle. Steps 2 and 3 are cycled 42 times before going to steps 4 
and 5. 
Step no. Temperature Time Function 
1 95 
o
C 3 min Initial denaturation 
2 60 
o
C 35 sec Annealing 
3 95 
o
C 10 sec Denaturation 
4 60 
o
C 35 sec Annealing 
5 95 
o








Intensity curves were viewed in iCycler iQ software version 3.1 (figure 2.5), 
removing any curves with dropping intensities from further analysis. Threshold 
position (the intensity corresponding to the threshold cycle Ct) is set at the beginning 
of the linear area of the curves, separated from the baseline level.  
 
Figure 2.5: Intensity curves from a qPCR experiment as viewed in iCycler. Baseline 
fluorescence (the fluorescence detected in the initial cycles) is set as 0. Threshold position is 
labeled in orange. Genes are rising above threshold level at different time points, forming 
separate groups.  
 
 38 
2.5.6 polyacrylamide electrophoresis of DNA 
Whenever a new protocol or new primers were employed, the sizes of the PCR 
products were controlled by DNA electrophoresis. Acrylamide gels were prepared in 
a dedicated PCR lab, as described in appendix E, and poured into a 15-well 
electrophoresis cell (Bio-Rad). When solid, 7 µl of qPCR product and 1.5 µl of 
nucleic acid loading buffer (Bio-Rad) was added to each well along with a λ HindIII 
DNA ladder (BioRad). The electrophoresis was run at 180V for 20 minutes using 
TAE (buffer composed of Tris base, acetic acid and EDTA) as the running buffer.  
The gel was then transferred to a container filled with TAE. 4 µl of nucleic acid gel 
stain (SYBR gold, Invitrogen) was added. The gel was transferred to another 
container of TAE to remove excess stain and photographed in a Gel Doc 2000 UV 
camera (Bio-Rad) using the associated software Quantitation One. The size of the 
amplified DNA molecules were compared with the known size of the transcripts 
created in the RT-PCR as a control for incorrect amplification products. 
2.6 Microarray experiments 
Part two of the project concerned downstream genes of our model gene, S100A4. By 
altering S100A4 expression with following expression profiling, we were aiming to 
identify genes that are influenced by S100A4 expression. This explorative approach 
is only possible when using profiling methods. 
Microarray technology measures the transcription level of thousands of genes in 
parallel (simultaneously) from a single RNA sample. This makes it possible to obtain 
a snapshot of the transcriptome of the cells. The procedure is highly automated, 
ensuring replicability of the data. 
Several platforms for microarray experiments are available, all utilizing the ability of 
nucleic acids to base pair to a specific nucleic acid probe. The base paired nucleic 
acids are detected, usually by fluorescence emitted by the probe. 
 39 
The Illumina microarray platform utilizes beads covalently bound to specific probes 
and a detectable tag for each probe (see figure 2.6). Each individual bead is bound to 
several identical probes. There may be more than one probe corresponding to each 
gene. The beads are distributed randomly across silicon slides, and the positions of 
the tags are detected in each individual array. On average, each array contains 30 
copies of each bead type.  
One sample is applied to each array. Upon hybridization of samples to arrays, 
hybridized beads fluoresce. The fluorescence is captured as a high-resolution image, 
and the fluorescence intensities in each spot are analyzed. [70] 
  
Figure 2.6: Bead with 23 bp code tag and a 50 bp probe, hybridized to biotinylated cRNA. 
The bead is 3 µm across, and bound to several probes (only one is shown). 
The data sets produced in a microarray experiment are vast, and require powerful 
software for data analysis. 
 
Experimental design 
Cells were transfected with 3 µg S100A4 mRNA, a dose which had shown high 
transfection yield after qPCR quantification. To monitor the relationship between 
dose and response, cells transfected with a lower dose of mRNA (1 µg) were also 
included in the analysis. Cells transfected with EGFP mRNA were used as a negative 
control. EGFP is presumed not to interact with other genes as the EGFP gene is 
foreign to the human cell. Ideally, only unspecific effects of the transfection itself 
should affect transcription in these cells. The experiments were done in two different 
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cell lines (LOX and OHS) to assess reproducibility across cell lines. Two biological 
parallels were used for each parameter, giving a total of 12 samples, as listed in table 
2.4. 
Table 2.4: Type and amount of mRNA used in the two different cell lines tested. Two 
parallels were made for each parameter, giving a total of 12 samples. 3 µl PEI was used as 
the transfection agent in all transfections.  
Gene Amount Cell line 
S100A4 1 µg OHS 
S100A4 1 µg LOX 
S100A4 3 µg OHS 
S100A4 3 µg LOX 
EGFP 3 µg OHS 
EGFP 3 µg LOX 
 
Total RNA was submitted to the Norwegian Microarray Consortium (NMC) 
Microarray Core Facility at the Norwegian Radium Hospital.  
The following procedures were done by in house laboratory staff at the facility:  
Small samples of the submitted RNA were quality checked on the Bioanalyzer 2100 
(Agilent, Santa Clara, USA). The Bioanalyzer separates the contents of the sample 
electrophoretically in microcapillaries. The distribution of RNA lengths is compared 
to a known distribution from the cell type in question. A shift towards shorter lengths 
indicates degradation of the sample. [71] The level of degradation is determined 
mainly from the ratio of the 28S to 18S rRNA peaks, which approach 2:1 in 
undegraded samples,[70] and is summarized in the RNA integrity number (RIN). 
RIN ranges from 1-10 where 10 indicates a very intact sample. RIN for samples used 
in microarray experiments should be above 7. [72]  
The RNA must be amplified in order to obtain a detectable signal in the microarray. 
As there are no known enzymes that make RNA from an RNA template, it must be 
transcribed to DNA first. Reverse transcription was done using oligothymine primers 
to generate cDNA from mRNA only. The primers include an upstream T7 promoter 
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region for use in the subsequent cRNA synthesis. After first strand synthesis, the 
RNA template was degraded and the 
second strand cDNA was transcribed. 
The double stranded cDNA was purified, 
and amplified as cRNA by T7 RNA 
polymerase in several cycles using a mix 
of unlabeled and biotin-labeled 
nucleotides.  
cRNA was quality controlled to assess 
integrity, purity, and concentration of the 
samples. 
The amplification procedure is 








Figure 2.7: Preparation of samples for the 
microarray experiment. Straight lines denote 
DNA, curled lines denote RNA, and 
asterisks denote biotin. Figure adapted from 
[70]. 
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The labeled cRNA was hybridized to a Sentrix BeadChip array with a HumanHT-12 
v4 probe set containing 47 000 probes covering the human transcriptome. The probe 
sequences in this probe set are derived from the gene database RefSeq. 
Unhybridized cRNA was then washed off the array and the amount of bound cRNA 
on each bead was detected using streptavidin-Cy3. The Cy3-labeled streptavidin 
binds strongly to the biotin in the cRNA. Cyanine 3 is a fluorescent marker that emits 
green light at a wavelength of ~570 nm when excited at ~550 nm.  Scanning of the 
slides was performed on a BeadArray Reader. The read-out from the scan results in 
large image files in which each bead shows up as spots of different brightness. Bright 
spots correspond to actively expressed genes. The data is converted to text files using 
the associated BeadStudio software, normalized and returned to the user along with 
the image files, a quality report including cluster analysis, and protocol files. 
 
2.6.1 Bioinformatic tools used in the analysis of microarray data 
The dataset was analyzed using the analysis software J-express [73] developed at the 
University of Bergen to identify genes that were significantly differentially expressed 
between experimental groups, with the help of Vegard Nygaard. The replicates were 
grouped together in the analysis. Different probes within the same genes were not 
grouped together, as some transcript variants may not span all probes. Quantile 
normalization and filtering to remove non-influenced genes was applied before 
analysis.  
The main analysis utilized for this study was the unparametric test statistic Rank 
Product, a robust test for few-replicate, normalized microarray datasets. [74, 75] The 
rank a gene is given takes into account both the difference in expression between the 
experimental groups, and the variation between parallel samples. Higher rank 
indicates higher probability of a real difference in expression. The analysis also gives 
a q-value for each gene. The q-value is a False Discovery Rate (FDR) adjusted p-
value; one of multiple options for multiple testing adjustment of the p-value. If a list 
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of genes is cut off at q=0.05, 5% of the entries in the list are expected to be false. 
Settings used for Rank Product: 400 permutations, random seed. Additionally, the 
Fold change viewer was used to envision distributions and magnitudes of expression 
changes.  
A set of six candidate genes was forwarded to qPCR validation based on the 
following criteria: 
 High rank, corresponding to being significantly influenced by the treatment. Preferentially 
in both cell lines included in the experiment. 
 Being relevant for one of the hallmarks of cancer, as determined by researching literature. 
Overrepresentation analyses were carried out by using the web based tool DAVID 
[76, 77] developed at the National Cancer Institute, US. This was done by matching 
each gene to a set of Gene Ontology terms, and then comparing the occurrence of 
each term to its occurrence within a random list of genes from the same organism. 
 
 
2.7 Protein analyses 
The fact that a gene is detected on the mRNA level is often taken as proof of protein 
expression. There are, however, several points of regulation before an mRNA is 
translated to protein. Some mRNAs are translated at a low level, or not at all, due to 
properties of their sequence causing the RNA strand to be sequestered or degraded. 
Protein expression analyses are hence necessary to know that the gene is actually 
translated. 
Unlike nucleic acids, protein is not easily amplified or sequenced. Immunological 
methods have thus proven invaluable for the indirect identification of protein. A 
typical workflow for the analysis of protein expression is to make lysates of the 
samples, measurement of the protein concentration before separating the proteins 
electrophoretically. The separated proteins are then transferred to a more durable 
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membrane material, and proteins of interest can be detected based on specific 
interactions with antibodies. 
 
2.7.1 Protein lysate 
Cell lysates for use in protein analyses were prepared using the following protocol: 
 Medium was removed by pipetting 
 1 ml PBS was added to each well 
 Cells were detached using a cell scraper 
 Suspension was transferred to Eppendorf tubes and pelleted by centrifuging at 2000 RPM 
for 5 minutes 
 Supernatant was removed by pipetting, and the pellet was frozen at -70 oC or -180 oC 
 25 µl lysis buffer (Appendix E) with protease inhibitors was added to frozen pellet 
 Cells were lysed on ice for a minimum of 15 minutes with repetitive vortexing steps. Cell 
lysates were then sonicated at 4oC by dipping the probe in the lysate for 3x3 seconds 
 Next, cell debris was pelleted by centrifuging at 15 000 RPM for 15 minutes at 4oC 
 Finally, the supernatant was transferred to new tubes and stored at -70oC. 
Of note, sonication causes the nuclear membrane to rupture, releasing nuclear 
proteins to the lysate. 
 
2.7.2 Measuring protein concentration 
The Bradford analysis of protein concentration utilizes a color reaction that can be 
quantified by spectrophotometry. The binding of the aromatic dye Coomassie 
Brilliant Blue G-250 (Bio-Rad) to protein changes the absorption maximum (Amax) of 
the solution from 465 nm to 595 nm. [78] By using a dilution curve of a reference 
protein with a known concentration, the concentration of the protein in the sample 
can be inferred. 
The dye binds primarily to Arginine side chains, and slightly to other basic and 
aromatic residues. [79] The amino acid composition of the protein therefore 
influences the level of dye binding. The protein lysate was assumed to have similar 
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overall amino acid composition as the reference protein bovine gamma globulin 
(BGG). 
Procedure: 
 A dilution curve of 0, 1, 2, 3, 4 and 5 µg of standard protein was made by pipetting 0, 2, 4, 6, 
8 and 10 µl of 0.5 µg/µl BGG in 3 parallels in a 96-well plate and adding H2O to 10 µl 
 1 µl of each lysate was pipetted on the plate in 3 parallels. H2O to 10 µl was added. 
 100 µl of dye was added to each well 
 After a minimum of 5 minutes incubation, the absorbance at 600 nm was read on a 
Modulus microplate spectrometer (Turner BioSystems) 
A standard curve for each plate was made in spreadsheet software. Protein concentrations 
in the samples were computed from the equation describing the curve. 
 
 
2.7.3 Polyacrylamide gel electrophoresis of proteins 
In electrophoresis, proteins or other macromolecules are separated based on size by 
the use of electric current. The secondary structures of the proteins are denatured by 
heat and the anionic detergent LDS (lithium dodecyl sulphate) to long polypeptide 
chains. Additionally, a reducing agent containing dithiothreitol (DTT, Cleland's 
reagent) reduces disulphide bridges in the protein. LDS binds to hydrophobic groups 
along the polypeptide, giving it a uniform negative charge that is proportional to the 
length of the protein. As the negative charges on LDS repel each other, the 
polypeptide is kept linear during the electrophoresis. When current is applied to the 
system, the negative charges are drawn towards the positive pole. 
The gel consists of a highly cross-linked polyacrylamide matrix. Longer peptide 
chains are hindered by the matrix to a higher degree than shorter ones. This causes 
small proteins to travel faster towards the positive pole, thus separating the proteins 
based on size. [6] 
LDS-PAGE (PolyAcrylamide Gel Electrophoresis) was done using the pre-cast 




A maximum of 22 µg protein was prepared for electrophoresis by adding de-ionized 
H2O to 6.5 µl, 2.5 µl NuPage sample buffer and 1 µl NuPage reducing agent (Bio-
Rad), and heated at 70
o
C for 10 minutes on a heat block.  
The well separator is removed from the gel, wells are rinsed with running buffer, and 
protective tape is removed from the bottom of the gel. The gel system is assembled 
and filled with running buffer (MOPS [3-(N-morpholino)propanesulfonic acid] 20 
mM, ~7 dl) to the fill line. Samples are applied carefully in the wells along with a 
ladder of markers (1 kb dual-color ladder, Bio-Rad, 2.5 µl). 
The electrophoresis is run on 180V until the marker proteins are sufficiently 
separated (~1 hr). 
 
2.7.4 Western Blot 
The gel matrix is unstable, and the separated protein spots need to be transferred to a 
more durable medium. This is accomplished using electric current. As in gel 
electrophoresis, the proteins carry a negative charge and will follow a current towards 
the positive pole. A membrane placed between the gel with samples and the positive 
pole retains the proteins but allows the buffer through. The protein spots adhere to the 
membrane in the same pattern as they were in the gel, as illustrated in figure 2.8. 
Proteins were transferred from the gel matrix to a nitrocellulose membrane with 0.2 
µm pore size using dry blotting (iBlot, Invitrogen) for 9 minutes. 
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Figure 2.8: Protein blotting set-up (Invitrogen).  
2.7.5 Antibody staining 
Antibodies are found in all vertebrates as part of the adaptive immune system. These 
small proteins bind specifically to epitopes (small motives, typically 5-6 amino acids) 
on an antigen, which can be any foreign substance, usually protein. Each antibody 
molecule has two identical antigen binding sites, each consisting of parts of the 
variable region of the light and heavy chain (see figure 2.9). The great versatility of 
the antibody specificities stem from the random recombination of the DNA sequence 
coding for the variable region. In the heavy chain, 4 gene segments are selected from 
a total of 87. A similar recombination happens in the gene for the light chain. This 
random selection of segments ensures an enormous diversity in the specificities of 
antibodies. A screening process in the bone marrow and thymus removes autoreactive 
antibodies that bind to innate structures of the body. The high specificity of the 
antibody binding makes them well suited for detection of specific proteins. 
Polyclonal antibodies are raised in mammals by injecting the antigen. The animal, 
e.g. a mouse, will produce antibodies against the antigen as part of its immune 
response against the foreign substance. The antibodies can later be isolated from the 
blood plasma and purified using affinity chromatography. Secondary antibodies are 
raised in another animal, e.g. a rabbit, using (in this example) mouse antibodies or 
parts thereof as the antigen. As the rabbit and mouse immunoglobulins differ in 
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structure, the rabbit interprets the antibodies of mouse origin as foreign and produces 
antibodies against them. After purification of rabbit-anti-mouse (RAM) antibodies 
specific for the constant regions of the mouse antibody, the secondary antibody is 
coupled to a detectable probe, commonly horseradish peroxidase (HRP) that can 
cleave a luminescent agent for detection. The RAM antibody can be used as a 
detector of any primary antibody raised in mouse. This two-step process lowers costs 
as the detection antibody can be produced in larger quantities more effectively than 
coupling all primary antibodies to probes. Polyclonal antibodies differ somewhat, as 
they arise from different B-cell clones and recognize different epitopes on the 
antigen. 
Monoclonal antibodies are produced by immortalized hybridoma cells. All 
monoclonal antibodies from the same clone are identical. [80] 
  
 
Figure 2.9: Schematic structure of IgG. Adapted from [81]. 
The antibody against S100A4 was purchased from Sigma and was raised in rabbit. 
The housekeeping gene α-tubulin was used as the loading control (antibody 
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purchased from Calbiotech, raised in mouse). Rabbit anti-mouse-HRP and goat anti-
rabbit-HRP (Daco) were used as secondary antibodies in this study.  
Procedure: 
 The membrane is incubated in 50 ml 10% dry milk in 0.25% TBST buffer 
(w/v) for a minimum of 1 hour to saturate the protein binding membrane.  
 Membrane is cut to give experimental and housekeeping genes on separate 
membranes 
 Membranes are incubated with primary antibody diluted in 5% dry milk in 
0.25% TBST buffer for a minimum of 1 hr or over night.  
 
The primary antibody-milk mixture can be used up to 4 times within 2 months. If the 
mixture is stored, 15 µl Na-azid is added after the first use as a conservant. 
 
2.7.6 Digital development 
ECL (Enhanced ChemiLuminescence, Thermo Fisher) is cleaved by HRP, producing 
a luminescent signal that is detected by the digital chemiluminescence imager G:box 
iChemi (Syngene; Cambridge, UK) with the associated GeneSnap software. Pictures 
were typically taken with 1, 2, 5 and 10 minutes exposure time and saved as high-
resolution image files (.tiff). 
 
2.8 Cell viability assay 
Transfection may induce reduction in cell viability, and optimizing of transfection 
protocols is usually performed to minimize unwanted cell death. 
MTS (Owen’s reagent; 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) is a yellow-colored tetrazolium compound that is 
reduced in living cells to a purple formazan compound in the presence of the electron 
coupling agent phenazine methosulfate (PMS), measured as an absorption shift from 
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382 to 490 nm. The reaction is shown in figure 2.10. The reduction is presumed to be 
caused by the reducing agents NAPD and NAPDH. In dead cells, with no metabolic 
activity, these compounds are rapidly depleted and reduction of MTS ceases. The 
level of the Formazan product is interpreted as proportional to the number of viable 
cells. [82, 83] 
 
Figure 2.10: Structures of MTS and the Formazan product. [84] 
In the present study, the CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay 
(Promega, Fitchburg, USA) was used to assess cell viability in transfected cells 
versus untreated cells by the following adapted protocol:  
 Cells grown in 12-well plates were transfected with or without PCI treatment and 
incubated 20-24 hrs. 
 A stock solution of 1:6 MTS in medium was made using 200 µl MTS solution in 
1000 µl RPMI with added serum and L-glutamine. 
 In dim light, 1 ml of the stock solution was added to each well. Untransfected cells 
were used as reference. A cell-free well (medium and MTS solution only) was used 
as a negative control.  
 The plates were incubated without light for 1-3 hours until a dark purple-brown color 
could be observed in some wells. Aluminum foil was used to ensure dark incubation. 
Checks for color change were performed every 30-40 minutes in dim light. 
 Absorption at 490 nm was quantified using a Victor 1420 spectrophotometer 
(Wallac, now PerkinElmer, Waltham, US). A490 should fall within the linear area 
(~0.6 to 1.4). The absorption of the no-cell condition was subtracted from all 
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3.1 Optimization of transfection protocol  
3.1.1 Flow cytometry 
Expression of EGFP protein after transfecting cells with EGFP mRNA was quantified 
using flow cytometry. Table 3.1 indicates the proportions of propidium iodide 
resistant (living) singlet cells among the 10 000 measured particles, as well as the 
percentage of EGFP expressing cells amongst singlet, PI negative cells, using PEI or 
cyclodextrin as the transfection agent, measured 24 hours after transfection.  
Initially, a broad PEI-based assay was carried out (table 3.1a). N/P 5 produced the 
best efficiency, with 50.5% of the cells expressing the transfected mRNA as protein. 
The PCI targeting effect was demonstrated; the PCI+ conditions exhibited a high 
transfection rate, versus low expression in the PCI- conditions. In this design, the 
amount of dead cells and cell fragments increased with increasing N/P ratio. PCI 
treatment induced a further reduction in viability. 
The transfection conditions that produced the best transfection rates in this assay (N/P 
3, 5 and 7) were forwarded to further refinement. 
When using β-6CDP (table 3.1b), only transfection rates up to 21% were obtained 
with the carrier concentrations assayed, with no additional effect from PCI treatment. 
Based on these results, it was decided to use PEI in the further studies of gene 
interactions. In this single-cell based study, transfection efficiency is of higher 
importance than cytotoxicity.  
After multiple rounds of refining transfection conditions (number of cells seeded and 
incubation times) transfection efficiencies up to 69.4% were observed (table 3.1c). 
Again, N/P 5 produced the best efficiency with PCI. All flow cytometry assays were 
done in OHS cells.  
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Table 3.1: Fractions of viable cells (PI-) and EGFP positive cells after transfection, as 
determined by flow cytometry. (a) Initial PEI-based transfection, (b) β-6CDP-based, (c) 
PEI-based after optimalization. PI negative, single cells are given as percentage of the total 
number of measured particles. Relative survival is PI- in percent of PI- in control. EGFP 
positive cell count is given as percentage of PI negative, singlet cells. Each value is the mean 
of measurements of two individual samples. Values marked with * are based on one sample. 
10 000 events were recorded per sample. All measurements were done in OHS cells. 
a)  





Viewing EGFP transfected cells in a microscope gives an overview of transfection 
efficiencies and cell survival. Figure 3.1 shows EGFP expression in cells when 
viewed at 20x magnification in a fluorescence microscope using a 488 nm filter. In 
transfections using N/P ratios 5 and 10 (left, middle), high transfection rates were 
observed in the PCI treated samples, while few non-PCI-treated cells had taken up the 
gene. In the N/P 15 transfection, a considerable number of cells took up the gene 
without the aid of PCI (“leakage”). In the N/P 15 PCI-assisted transfection, several 
dead or dying cells are observed as circular spots. 
 
Figure 3.1: EGFP transfected OHS cells viewed at 20x magnification 24 hours after 
transfection. Top panels are transfected without the use of PCI, bottom panels are PCI 
treated. 
3.2 Measurements of S100A4 delivery  
Once an efficient protocol for PEI-mediated, non-PCI mRNA delivery was 
established, delivery of S100A4 was confirmed on the mRNA and protein level. The 
parameters used for the transfections assessed in this section are listed in table 2.1. 
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3.2.1 RNA analysis 
Quantitative real-time PCR (qPCR) of RNA isolated from transfected cells 24 hours 
after transfection confirms successful delivery of S100A4 mRNA into cells, as shown 
in figure 3.2. The amount of S100A4 recovered from the cells is higher in the 
samples that received a higher dose of S100A4 mRNA in the transfection. The lowest 





Figure 3.2: Relative expression of S100A4 mRNA in (a) LOX and (b) OHS samples treated 
with 0, 1, 2 or 3 µg S100A4 mRNA combined with 3 µg PEI, as detected by qPCR. 3 
individual samples are shown for each dosage, with 2 replicate measurements per sample. 
Untreated controls are set to 1. Error bars denote standard deviation. Note that the expression 
scales differ between the cell lines. 
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3.2.2 Protein expression analysis 
Western blots 
Western blots confirm expression of S100A4 protein 24 hours after transfection, as 
presented in figure 3.3. In LOX cells (fig 3.3a), results showed that  transfection 
using 1 µg S100A4 mRNA produced relatively weak bands, 2 µg mRNA produced 
slightly brighter bands, while the strongest bands were found when using 3 µg 
S100A4 mRNA. Of note, no band was visible in the untransfected cells in agreement 
with the fact that the LOX cell line is negative for S100A4 expression. 
In the OHS cell line (fig 3.3b), the protein level of S100A4 was more challenging to 
quantify due to the high innate S100A4 expression. Our results showed that all 
experimental groups exhibited a high level of S100A4 protein. An upregulation may 





Figure 3.3: Western blots of S100A4 (bottom) and α-tubulin (indicator of loading volume; 
top) in (a) LOX and (b) OHS cells. Three individual replicates for each condition were 
blotted in the same blot. Lanes 1 to 3 from right to left: Untransfected cells. Lanes 4 to 6: 1 
µg S100A4 mRNA. Lanes 7 to 9: 2 µg S100A4 mRNA. Lanes 10 to 12: 3 µg S100A4 
mRNA.  
 57 
3.3 Target gene expression analyses 
3.3.1 Expression microarray profile 
A clustering analysis was done on the expression profile as a quality check, as shown 
in figure 3.4. Samples that received identical treatment are expected to cluster 
together. One sample of EGFP transfected LOX cells was excluded from further 
analyses due to clustering differently than the rest of the samples from the LOX cell 
line. Therefore, the S100A4 treated LOX samples were compared to a baseline 
consisting of only one sample. 
 
Figure 3.4: Samples clustered based on similarity in expression pattern. The sample labeled 
LOX EGFP (1) clustered together with the OHS samples and was excluded from further 
analyses. 
 
To identify differentially expressed genes, the Rank Product analysis [74] was 
employed with a q-value cut-off of 0.05. Top results of these analyses are shown in 
table 3.2.  
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Table 3.2: Rank Product of control versus transfected samples for both cell lines combined 
(a), OHS (b), (c), and LOX (d), (e). Genes in boldface were selected for further validation of 
differential expression.  
 
A set of six genes which had high ranks (below the q=0.05 threshold in at least one 
comparison) and were relevant for cancer progression were selected for wet-lab 
validation. The expression pattern of the chosen candidate genes in the array are 
shown in table 3.3. 
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Table 3.3: Expression and fold change for candidate genes in control and treated samples. 
Expression values are quantile normalized and given as the mean of two parallel samples, 
except for the EGFP control in LOX which is only one measurement. Fold change 
calculation was done in J-express.  
 
Overrepresentation analysis 
A list of 100 top differentially expressed genes was obtained using Rank Product for 
control versus 3 µg treated samples in both cell lines combined, ignoring hypothetical 
and predicted genes that are not recognized by the overrepresentation analysis tool. 
When comparing this list to a random human reference using the web application 
DAVID, Gene Ontology (GO) terms associated with the extracellular space were 
significantly overrepresented, as shown in table 3.4.  
Table 3.4: Screenshot from DAVID software, showing the four most significantly 
overrepresented Gene Ontology terms associated with the set of 100 top ranked genes from 
the expression profile of OHS and LOX cells combined. 
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3.3.2 qPCR validation 
Figure 3.5 summarizes the result of qPCR using primers for candidate genes from the 
expression microarray. Ct values are listed in appendix B. The graphs to the right 
show the intensities in the microarrays for comparison.  
a)              
b)   
c)                
d)         
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e)                    
Figure 3.5: Relative expression of (a) CT10, (b) Col1a2, (c) ADAM15, (d) LCN12, (e) 
SNORA71c and (f) LOC646469 as determined by qPCR. The second axis shows the fold 
change. Expression in EGFP transfected samples (K) is set to 1. Each bar represents the 
average of 3 individual experiments for LOX, and 2 individual experiments for OHS. Graphs 
showing the intensity for each of the genes in the microarray analysis are included on the 
right side for comparison. 
CT10 did not pass qPCR validation. 
Col1a2 did show a similar expression pattern in the qPCR as in the microarray, 
however the magnitude of the changes deviated: LOX cells had a 23% increase 
followed by a 2.5 fold decrease in the qPCR (microarray: 3 fold increase followed by 
2.8 fold decrease). OHS cells had a 4.35 fold increase followed by a 2.3 fold decrease 
(microarray: 15% increase followed by a 19% decrease). Further validation would be 
necessary to establish whether Col1a2 really is regulated by S100A4. 
 ADAM15 did not pass qPCR validation. 
LCN12 downregulation was confirmed by qPCR validation. In LOX, the decrease in 
expression was about one fold between control and treated samples combined 
(microarray: three fold decrease).  In OHS, the decrease was about seven fold 
(microarray: five fold decrease).  
SNORA71c did not pass qPCR validation. 
Validation of LOC646469 was attempted, but was unsuccessful, likely due to primer 
dimerization. 
 
3.3.3 Primer validation by electrophoresis of transcripts 
Shown in figure 3.6 are qPCR transcripts separated by gel electrophoresis. Expected 
transcript lengths are found in Appendix C. Observed transcript lengths are in good 
accordance with expected lengths. A smear at about 25 bp is visible for LOC646469, 
indicative of erroneous transcripts. 
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Figure 3.6: DNA electrophoresis gel picture showing the lengths of qPCR transcripts. 
Theoretical transcripts lengths in basepairs: CT10: 95, Col1a2: 62, ADAM15: 77, LCN12: 73, 
SNORA71c: 80, LOC646469: 66, S100A4: 79, TBP: 64, RPLP0: 64 
 
 
3.4 Particle size measurements 
Particle sizes after complexion of mRNA and PEI using different mRNA 
concentrations were measured using a Malvern Zetasizer. 1, 2 and 3 µg S100A4 
mRNA complexed with 3 µg PEI corresponding to N/P 22, 11 and 7.3 respectively, 
was measured starting after 30 minutes. Results are shown in table 3.5. 
Table 3.5: Sizes of transfection particles in nm (largest peak). 
 
There was considerable variation in the measured particle sizes. Incubation time was 
observed to be an important factor for particle size; when incubated for 60 minutes, 
particle sizes up to 1000 nm were observed. Further details are listed in Appendix D. 
β-CDP-based particles were too polydisperse to be measured with this equipment. 
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3.5 Cell viability assays 
Cell viability was assessed using the MTS assay 20 hours after mRNA transfection 
using parameters listed in table 2.1 with and without PCI treatment. In the non-PCI 
transfection, a 10% reduction in cell viability is observed in the LOX cell line in the 1 
µg transfection, which has the highest positive charge. This reduction becomes 
smaller in the higher mRNA conditions, which have a more neutral charge. No 
reduction in cell viability was observed in the OHS line.  
In the PCI-assisted transfections, a 25-30% reduction in viability was observed for 
the higher N/P ratios in the assay when compared to the same transfections without 
PCI treatment. In the lowest ratio in the assay, the viability difference between PCI 




Figure 3.6: Cell viability after transfection. a) Without PCI treatment, conducted in LOX and 
OHS cells using fixed concentrations of PEI with varying concentrations of mRNA. b) PCI 
assisted transfections conducted in OHS cells with fixed concentrations of mRNA and 
varying concentrations of PEI. Each bar is the average of three different transfections. The 
error bars show the standard deviation. 
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4. Discussion 
4.1 Gene therapy and transfection 
4.1.1 Methodical considerations 
An mRNA-based upregulation study can be regarded as the opposite of a siRNA 
downregulation study, using the same set of procedures to influence the gene 
expression of cells in two opposite ways. A few notable differences exist; siRNA are 
easily synthesized and commercially available in contrast to mRNA molecules. 
siRNA molecules consist of two short double mRNA strands (19-21 bp), while 
mRNA transcripts are single stranded and much longer. The size difference of the 
molecules will naturally influence the formation of transfection complexes, as 
discussed below.  
The two cell lines chosen for the study are quite different, most strikingly in terms of 
endogenous S100A4 expression, but also in cell type origin. LOX is an amelanotic 
melanoma line derived from melanocytes of the skin, while OHS is an osteosarcoma 
cell line derived from retinoblastoma origin. It is therefore expected that the cell lines 
have different expression patterns, in addition to different endocytotic capacity.  
Flow cytometry was used in the initial part of the project, to assay a broad range of 
transfections designed for use with PCI. PCI directed transfection was demonstrated. 
In the rest of the study, transfections designed for use without PCI were employed. 
For this, a PEI concentration just above the point where leakage occurs was 
identified. The high PEI concentrations for use without PCI were not investigated 
using flow cytometry, but delivery and protein expression were instead confirmed 
using qPCR and Western blotting. 
β-6CDP has been shown to be effective with siRNA, [34] but performed poorly with 
mRNA. Other transfection agents also deliver siRNA better than mRNA 
(unpublished results from the research group of E. Hovig). This could be because 
siRNAs are shorter, giving more options for the conformation of complexes. In 
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support of this hypothesis, the Zetasizer was unable to measure the size of the β-
6CDP-based complexes due to high polydispersity. 
 
4.1.2 Internalization mechanisms  
Both PEI- and β-6CDP-based complexes are cationic and are theorized to adhere to 
the cell based on electrostatic interactions. β-CD is additionally hypothesized to bind 
cholesterol on the plasma membrane. [32] The adhesion to cholesterol would require 
the particle to be in direct contact with the plasma membrane, which seems unlikely 
knowing the cell surface is covered with carbohydrate chains. 
The transfection particles range from 370 to 540 nm. The literature is conflicting 
regarding which mechanisms of endocytosis are at play for particles in this size 
range. [45, 85] It is difficult to determine internalization mechanisms in blocking 
studies, as the involved genes tend to act in more than one pathway.  
RNA is easily degraded. Though it is to a degree protected by the complexation 
agent, it must exit the endocytic pathway at an early stage to reach the cytosol in an 
intact state, as the environment gets progressively more degrading as the endosomes 
mature. The timespan from a material is endocytosed until it reaches the lysosomes is 
highly variable, often in the range of ~5 to 30 minutes depending on which pathway 
is employed [86]. In PCI-based trials with a 4 hrs chase, the material that was 
endocytosed shortly after adding the complexes to the cells, have reached the 
lysosomes long before the light treatment. The complexes that are released in the 
light treatment were endocytosed in the latter part of the chase. This means there 
needs to be enough transfection complexes to uphold a high internalization rate 
throughout the chase period. 
In non-PCI, proton sponge based transfections, the swelling is dependent on the 
acidification of endosomes, giving continuous release to the cytosol for as long as 
transfection complexes are endocytosed or until cells are harvested. This may give 
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more mRNA to each cell than the light-directed transfection which gives release from 
endosomes at only one time point. 
4.2 Microarray experiment  
4.2.1 Methodical considerations 
The microarray experiment included two biological replicates of each experimental 
condition. The parallels were prepared on the same days, from different cell culture 
plates. Two biological parallels are considered to be few in the context of 
microarrays; 4 to 5 are recommended. With fewer replicates, expression changes 
need to be larger in order to be detected in the statistical analysis. It is important to 
determine whether the analysis gives reliable results for groups of two parallel 
samples. With a lower number of parallel samples, the experiment is also vulnerable 
if a sample does not pass post-experiment quality controls, as was the case in the 
LOX control condition in this study. Additionally, the data are expected to have a 
relatively high degree of noise because the samples consist of a mixture of affected 
and unaffected cells.  
The control condition was transfected using the same parameters as the experimental 
condition, but with EGFP mRNA in place of S100A4 mRNA. These samples are 
expected to have unspecific expression changes caused by the transfection itself, but 
no specific expression changes caused by the transfected gene as EGFP is foreign to 
human cell lines. This gives a baseline from which the specific changes can be seen. 
Two concentrations of S100A4 mRNA were used in order to be able to determine a 
dose-response relationship. 
It should be noted that the mRNA transcriptome as detected by expression microarray 
profiles are not necessarily analogous to the protein expression of the cell, due to 
regulatory mechanisms in the translation step (as reviewed in [87]). 
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4.3 S100A4 gene interactions 
4.3.1 Selection of candidate interacting genes 
The expression profiling identifies genes whose expression is influenced by the 
presence of S100A4. It does not distinguish between direct interactions (e.g. S100A4 
acting as an activator of transcription) and indirect interactions (e.g. S100A4 
influencing the activity of another transcription factor). A significant difference in the 
profile is therefore not proof of a direct interaction between S100A4 and the affected 
gene.  
Microarray data are inherently noisy, and it is not always possible to distinguish real 
signals from noise. Therefore, results obtained in a microarray experiment should 
always be validated using qPCR or Northern or Western blotting. [87] For low-
frequency genes, the methodical noise is larger. [88]The genes selected for validation 
of differential expression were among the genes that showed the most significant 
differential expression in the microarray profile, as shown in table 3.2. Some of the 
selected candidate genes were present at a quite low frequency, and difficulties in 
validation were therefore expected. These genes were nevertheless forwarded to wet-
lab validation due to interest in their biological function.  
Candidate interacting genes: Validation 
Two of the five successfully amplified candidate genes passed qPCR validation. This 
is low, considering the significant differential expression of all candidates in the 
microarray (all were picked from rank product lists with q<0.05). This analysis does 
not take into account the magnitude of the intensity in the microarray. Probes with 
low intensities, such as CT10, have a larger variation because of a lower pool of 
transcript in the amplified sample. [88]  
Additionally, the hypothetical gene LOC646469 was not successfully amplified in 
qPCR. This sequence is somewhat repetitive, and we were therefore unable to design 
primers with no self base pairing.  
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4.3.2 Interacting genes 
Of six candidate interacting genes two were confirmed to be influenced by S100A4 
expression, three failed to validate and one was not validated due to methodical 
difficulties. 
LCN12 
The gene LCN12, coding for the transporter lipocalin 12, was shown to be 
transcriptionally regulated by S100A4. 
The lipocalins derive their name from greek; lipos, meaning fat, and calyx, meaning 
cup. This diverse family of small, mainly secreted carrier proteins in the calycin 
superfamily is found in eukaryotes and eubacteria. [89] The proteins have an eight-
stranded beta barrel forming the cup-shaped cargo binding site, in addition to binding 
to specific cell-surface receptors and the ability to form complexes with other 
proteins via its loop domain. Lipocalins are implicated in a number of biological 
processes including retinoid binding, cancer cell interactions, maintenance of 
homeostasis, and immune response. Cargo include steroid hormones, retinoids, and 
lipids, all of which are small, hydrophobic molecules. The lipocalin binds specific 
receptors on the cell surface, either to be endocytosed or releasing its cargo which 
migrates passively through the plasma membrane. [90]  
Several of the lipocalins have protease inhibitor activity, contributing to the cancer 
relevant part of their function, interfering with the migratory ability of the cancerous 
cell. [91]  
Lipocalin 12 [92] is normally expressed in the epididymis in response to androgen 
stimulation, and ex situ expression is reported in several cancers. While not 
completely characterized, is proposed to act in the transport of retinoic acid to the 




This subunit of type I collagen was upregulated in samples treated with a low dose of 
S100A4 mRNA, but not in those receiving a high mRNA dose. This surprising 
pattern was recurring in both cell lines studied, consistent in the microarray and 
qPCR. Interfering with the extracellular matrix, including collagen, is an important 
part of the cell invasion process in the metastatic cascade, and type I collagen is 
dysregulated in a range of cancers. A study found induction of a matrix protease by 
type I collagen. [94]  
LOC646469 
This hypothetic gene showed the largest fold change among all genes in the 
microarray experiment and was therefore included in the qPCR validation although 
its function is unknown. The sequence lacks introns, and samples were therefore 
treated with DNAse to remove any genomic material before qPCR analysis. qPCR 
data show that the amplification reached Ct very late, if at all, indicative of quality 
issues with primers which was also confirmed by electrophoresis of qPCR fragments. 
There is a chance of DNA contamination in the RNA used in the microarray 
experiment as this RNA was not treated with DNAse, this does however not explain 
the large increase in measured LOC646469 expression in treated samples. 
Overrepresentation analysis 
The overrepresentation of several terms associated with the extracellular space within 
the list of genes affected by S100A4 expression, is in accordance with earlier findings 
linking S100A4 to metastasis. 
 
4.4 Validations and quality controls 
The efficacies of the transfections were confirmed on the mRNA and protein levels. 
The timescale of the study did not allow for validation of candidate target genes on 
the protein level.  
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The use of two cell lines; one cell line with innate S100A4 expression and one 
completely lacking it, adds broadness to the study. 
Cell viability: The data suggest that the LOX cell line is more sensitive to positive 
charge than OHS. PCI treatment in transfection enhances uptake of mRNA, but also 
increases cell death due to increased membrane rupture.  
 
4.5 Conclusions 
A technique for mRNA transfection was refined to give good transfection efficacy 
while keeping high cell viability. 
S100A4 tranfection influences a range of genes, among which genes associated with 
the extracellular space are overrepresented. 
The transporter protein lipocalin 12 is a target gene of S100A4. To our knowledge, 
this relationship has not been reported before. Additionally, the collagen precursor 
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Ct-values for S100A4 
Ct-tables for qPCR quantitation of S100A4. For each replicate sample, two 
measurements were done. 
Table A1: Ct-values for quantitation of S100A4 in OHS cells. a) Data used for creating the 
graph shown in figure 3.2b. Fold change is relative to the sample with the highest Ct value. 
Missing values indicate no deviation. Samples also used in microarray expression profiling 





Table A2: Ct-values for quantitation of S100A4 in LOX cells. a) Data used for creating the 
graph shown in figure 3.2a. Fold change is relative to the sample with the highest Ct value. 
Missing values indicate no deviation. b) Ct data for samples used in microarray experiment.  
a)  






Ct-values for candidate genes 
Table B1: Ct-values for quantitation of candidate genes CT10, Col1a2, ADAM15, LCN12, 
and SNORA71c a) in LOX and b) OHS cells, used for creating the graphs shown in figure 
3.5. Fold change is relative to the sample with the highest Ct value. Missing values indicate 
no deviation.  
 









Primers used in the qPCR reactions. Melting temperature (Tm) is calculated from the 
percentage of G and C nucleotides in the primer sequence.   
Gene symbol Primer 
direction 






































































Particle size measurements 
Graphical representation of sizes of transfection particles. a) 1 µg mRNA. Main peak 
average: 377 nm. b) 2 µg mRNA. Main peak average: 534 nm. c) 3µg mRNA. Main peak 
average: 540 nm. Two peaks of differently sized particles are observed in each measurement; 
one large peak, and a smaller peak of smaller sized particles. The smaller peaks are 







Buffers and solutions used in the study 
Table E1: Growth medium supplements 
Supplement Concentration Per 500 ml RPMI 1640 
Fetal calf serum 10% 50 ml 
glutaMAX 2 mM 5.5 ml of 200 mM stock 
 
Table E2: Constitutents of freeze medium 
Constituent Volume 
RPMI 1640 w/serum, L-glutamine 16.5 ml 
Fetal calf serum 1.5 ml 
DMSO (sterile) 2 ml 
 
Table E3: Constituents of qPCR master mixes. Listed volumes were multiplied with the 
number of samples plus two (negative control plus a surplus to allow for pipetting error). 
Reagent Volume per sample in assay 
iQ SYBR Green Supermix 30 µl 
Primer reverse, 10 pmol/µl 1.8 µl 
Primer forward, 10 
pmol/µl 1.8 µl 
Sterile H2O 16.4 µl 
Total 50 µl 
 
Table E4: Constituents of acrylamide electrophoresis gels. After addition of TEMED, the gel 
is solid within 10-15 minutes.  
Reagent Volume Producer 
TAE 1x  9.6 ml  Invitrogen 
Acrylamide 40%  2.25 ml  Bio-Rad 
Ammonium persulfate (APS) 20%, freshly thawed (less 
than 4 weeks since thawed) 90 µl  Bio-Rad 




Table E5: Constituents of lysis buffer. 
Lysis buffer: 
 
For 50 ml: 
 Compound Concentration Compound Volume 
NaCl 150 mM 5 M NaCl 1.5 ml 
Tris pH 7.5 50 mM 0.5 M Tris pH 7.5 5 ml 
Nonidet P40 0.10% Nonidet P40 50 µl 
Double distilled H2O 
 
Double-distilled H2O to 50 ml 
 
The solution was stored at 4
o
C. 
Protease inhibitors PMSF, leupeptin, pepstatin, and aprotinin (all 2 mM; Sigma-Aldrich) 
were added to the lysis buffer before use; 10 µl of each to 1 ml of lysis buffer. 
 
Table E6: Preparation of protein samples for gel electrophoresis. 
Compound Volume (µl) Producer 
Sample X   
de-ionized H2O to 6.5   
NuPage LDS sample buffer 
(4x) 2.5 Bio-Rad 
NuPage Reducing Agent 1 Bio-Rad 
Total 10   
Directly after the addition of reducing agent, samples were heated at 70
o
C on a heat 
block for 10 minutes.  
 
Table E7: Contents of 0.25% TBST buffer: 
Compound Volume 
Tris pH 7.5 1M 20 ml 
NaCl 5M 100 ml 
Tween 20 2.5 ml 
double destilled H2O to 1 l 
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